IN THE UNITED STATES DISTRICT COURT

KELLYN CLAY,
  Plaintiff,

v.

UNITED STATES OF AMERICA,
by and through its agencies including but not limited to
the Central Intelligence Agency (CIA), Department of Defense (DoD),
and Department of Justice (DOJ),

and

WILLIAM ALTON CLAY,
individually and in his capacity as executor of the Estate of Eugenia Clay Head,

and

PALANTIR TECHNOLOGIES INC.,
a private defense contractor headquartered in Denver, Colorado,

and

JOHN DOE CONTRACTING AGENCIES AND AFFILIATES,
whose names and identities are presently unknown,

and

AMAZON.COM, INC.,
a multinational e-commerce corporation headquartered in Seattle, Washington,

and

REV.COM, INC.,
a transcription and captioning services company headquartered in Austin, Texas,

and

PAPERBOY MARKETING,
a flyer distribution company operating in the Twin Cities under successive ownership during the period of Plaintiff’s employment,

and

ELLIE FAMILY SERVICES, n/k/a ELLIE MENTAL HEALTH, a private mental health services corporation headquartered in Mendota Heights, Minnesota,
  Defendants.

⸻ 

Memorandum of Law Re: Anomaly Labeling Based on Involuntary Biofluid Substance Detection

⸻

Issue

Whether the detection of substances in an individual’s urine or other biofluids, which the individual did not knowingly or willingly consume, may serve as a legitimate basis for labeling that individual an “anomaly” in continuity, surveillance, or behavioral futures systems.

⸻

Background
	•	Anomaly classifications are often justified as responses to deviations from expected patterns of health, behavior, or compliance.
	•	Biofluid analysis is one of the most common data points used to flag individuals for such classification.
	•	In cases of Mast Cell Activation Syndrome (MCAS) or other chronic health vulnerabilities, the individual may have a narrow tolerance profile and consciously avoids most medications or substances.
	•	If substances appear in biofluids that the individual did not knowingly or voluntarily consume, the anomaly signal may not reflect personal behavior, but rather nonconsensual exposure or adversarial dosing.

⸻

Analysis
	1.	Consent as a threshold factor
	•	Classifying someone as an anomaly based on involuntary dosing collapses the distinction between autonomous behavior and external interference.
	•	This undermines both the fairness and accuracy of anomaly classification.
	2.	Reliability of anomaly classification
	•	A biofluid “hit” alone cannot establish consent or intent.
	•	Without corroborating evidence of voluntary ingestion, labeling the subject an anomaly risks misclassification.
	3.	Systemic manipulation
	•	Where adversarial systems (e.g., implants, covert fortification, contaminated supply chains) are suspected, anomalous biofluid results are more probative of hostile interference than of the subject’s agency.
	4.	Legal and ethical implications
	•	Nonconsensual dosing violates basic rights to bodily autonomy.
	•	Using such dosing as the basis for anomaly classification compounds the harm: the subject is both poisoned and stigmatized.

⸻

Conclusion

Anomaly labeling based on substances detected in biofluids—without confirming knowledgeable and voluntary ingestion—is neither valid nor justifiable. In cases where individuals have declared extremely narrow substance tolerances, any detection outside that range should be treated as evidence of nonconsensual dosing, not grounds for anomaly designation.

Respectfully submitted,
Kellyn Clay, Plaintiff, pro se 
